ERA

Download the full-sized PDF of Aerosol phage therapy for in vivo Burkholderia cepacia complex respiratory infectionsDownload the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R36M3397Q

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

Aerosol phage therapy for in vivo Burkholderia cepacia complex respiratory infections Open Access

Descriptions

Other title
Subject/Keyword
aerosol phage therapy
in vivo phage therapy
nose only inhalation device
Burkholderia cepacia complex
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Semler, DD
Supervisor and department
Dennis, Jonathan (Biological Sciences)
Examining committee member and department
Nargang, Frank (Biological Sciences)
Szymanski, Christine (Biological Sciences)
Foght, Julia (Biological Sciences)
Department
Department of Biological Sciences
Specialization
Microbiology and Biotechnology
Date accepted
2013-01-31T14:33:35Z
Graduation date
2013-06
Degree
Master of Science
Degree level
Master's
Abstract
In recent times, increased attention has been given to evaluating the efficacy of phage therapy, especially in scenarios where the bacterial infectious agent of interest is highly antibiotic resistant. In this regard, phage therapy is especially applicable to infections caused by the Burkholderia cepacia complex (BCC) since members of the BCC are antibiotic pan-resistant. Aerosol drug delivery is a common therapeutic delivery method for respiratory ailments and yet aerosol phage therapy has not previously been demonstrated to be effective for BCC infections. This study outlines the development of an in vivo model for evaluating aerosol delivery of phage therapeutics using a Nose-Only Inhalation Device (NOID). Immunocompromised mice infected with Burkholderia cenocepacia demonstrated a significant reduction in bacterial concentration when treated 24 h post-infection provided that the phage therapeutic was delivered at a sufficient concentration. This method shows promise for future evaluation of aerosolised respiratory phage therapeutics.
Language
English
DOI
doi:10.7939/R36M3397Q
Rights
Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication
Semler DD, Lynch KH, Dennis JJ. 2011. The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections. Front. Cell. Infect. Microbiol. 1:27.Hoe S, Semler D, Goudie A, Lynch K, Matinkhoo S, Finlay W, Dennis J, Vehring R. In press. Respirable bacteriophages for the treatment of bacterial lung infections. J. Aerosol Med. Pulm. D.

File Details

Date Uploaded
Date Modified
2014-04-29T15:18:53.781+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 1877014
Last modified: 2015:10:12 18:26:49-06:00
Filename: Semler_Diana_Winter2013.pdf
Original checksum: d3f1b90aff25ecfd0b741de8e1259d64
Well formed: true
Valid: true
File title: -
File author: Diana Semler
Page count: 127
File language: en-US
Activity of users you follow
User Activity Date